Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview-Reference-Cited by-同舟云学术

Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hobson Claire Amaris¹,Pierrat Gautier¹,Tenaillon Olivier¹,Bonacorsi Stéphane¹²,Bercot Béatrice¹³^ORCID,Jaouen Ella¹,Jacquier Hervé¹³,Birgy André¹²^ORCID

Affiliation:

1. IAME, UMR 1137, INSERM, Université Paris Cité, Paris, France

2. Service de Microbiologie, Hôpital Robert-Debré, AP-HP, Paris, France

3. Service de Bactériologie-Hygiène, Groupe Hospitalier Saint-Louis – Lariboisiere - Fernand Widal, AP-HP, Paris, France

Abstract

First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam.

Funder

ARC (association recherche contre le cancer) foundation

Fondation pour la Recherche Médicale

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00447-22

Reference119 articles.

1. Infections Caused by Carbapenem-resistant Gram-negative Pathogens in Hospitalized Children

2. Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in Italy